Endpoint | MRI−/CRP− | MRI+/CRP− | MRI−/CRP+ | MRI+/CRP+ | |
---|---|---|---|---|---|
ASAS40 | ETN | 2/17 (11.8) | 8/32 (25.0) | 3/11 (27.3) | 20/35 (57.1)† |
PBO | 2/21 (9.5) | 6/42 (14.3) | 1/10 (10.0) | 7/31 (22.6) | |
ASAS20 | ETN | 7/17 (41.2) | 14/32 (43.8) | 7/11 (63.6) | 24/35 (68.6)* |
PBO | 5/21 (23.8) | 16/42 (38.1) | 3/10 (30.0) | 13/31 (41.9) | |
ASDAS-CRP | ETN | 5/17 (29.4) | 12/31 (38.7) | 6/11 (54.5) | 27/35 (77.1)‡ |
PBO | 2/21 (9.5) | 7/42 (16.7) | 5/10 (50.0) | 10/32 (31.3) | |
ASDAS-ESR | ETN | 6/17 (35.3) | 12/28 (42.9) | 4/11 (36.4) | 25/33 (75.8)‡ |
PBO | 3/21 (14.3) | 9/42 (21.4) | 2/10 (20.0) | 8/29 (27.6) | |
BASDAI50 | ETN | 4/17 (23.5) | 10/32 (31.3) | 4/11 (36.4) | 25/35 (71.4)‡ |
PBO | 4/21 (19.0) | 11/42 (26.2) | 2/10 (20.0) | 9/32 (28.1) |
↵* p<0.05, †p<0.01, ‡p<0.001 vs PBO. Values are patients achieving endpoint n/N (%). Values for ASDAS-CRP/ESR are patients achieving clinically important improvement Δ≥1.1.